Furthermore, previous studies have shown that Pyk2 promoted EMT, invasion, metastasis, and recurrence in breast cancer by modulating various signaling pathways, suggesting that Pyk2 is one of the most promising metastatic biomarkers in cancer.[50, 51] Although several Pyk2 inhibitors have been developed and have achieved strong anti‐tumor effects in multiple tumor xenograft models,[52] their role in tumor immunity remains unclear. This evidence concerns the gene PTK2B and breast carcinoma.